Differentiate dementias using brain imaging
- Trial ID
- NCT03019757
- Official Title
- Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- Goal
- Differentiate dementias using brain imaging
- Status
- RECRUITING
- Sponsor
- Douglas Scharre
- Study Type
- OBSERVATIONAL
- Enrollment
- 76 participants
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
- Interventions
- DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, Clinical Assessment
Plain-Language Summary
The trial aims to help doctors tell Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease apart, because they can look similar but have different causes and treatments. It combines brain scans and tests to find distinct patterns, using DaTscan to measure dopamine transporter loss that points to Parkinsonian syndromes, F18-AV-45 amyloid PET to detect Alzheimer plaques, FDG-PET to map abnormal brain metabolism, APOE genotyping for Alzheimer risk, overnight polysomnography to detect REM sleep behavior disorder common in Lewy body disease, and detailed clinical and cognitive exams. Adults 18 and older who meet standard clinical criteria for one of these diagnoses, have an MMSE of 10 or higher, are on stable cognitive or psychoactive medications for at least four weeks, and have a study partner in regular contact are eligible. People with other medical causes of dementia, severe kidney impairment, pregnancy, less than 12 years of education, non,English first language, or prior exposure to an amyloid-targeting drug (unless only placebo) are excluded.
Locations
- The Ohio State University, Columbus, Ohio, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying DaTscan. The trial aims to help doctors tell Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease apart, because they can look similar but have different causes and treatments. It combines brain scans and tests to find distinct patterns, using DaTscan to measure dopamine transporter loss that points to Parkinsonian syndromes, F18-AV-45 amyloid PET to detect Alzheimer plaques, FDG-PET to map abnormal brain metabolism, APOE genotyping for Alzheimer risk, overnight polysomnography to detect REM sleep behavior disorder common in Lewy body disease, and detailed clinical and cognitive exams. Adults 18 and older who meet standard clinical criteria for one of these diagnoses, have an MMSE of 10 or higher, are on stable cognitive or psychoactive medications for at least four weeks, and have a study partner in regular contact are eligible. People with other medical causes of dementia, severe kidney impairment, pregnancy, less than 12 years of education, non,English first language, or prior exposure to an amyloid-targeting drug (unless only placebo) are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 8 years and 3 months.